Plasma exchange in ANCA-associated vasculitis: the pro position
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F21%3A10428663" target="_blank" >RIV/00216208:11110/21:10428663 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/21:10428663
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=zm82Pywdfa" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=zm82Pywdfa</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/ndt/gfaa311" target="_blank" >10.1093/ndt/gfaa311</a>
Alternative languages
Result language
angličtina
Original language name
Plasma exchange in ANCA-associated vasculitis: the pro position
Original language description
Plasma exchange (PLEX) is capable of removing significant amounts of circulating antibodies. In anti-neutrophil cytoplasmic antibody-associated vasculitis, PLEX was reserved for patients with severe presentation forms such as rapidly progressive glomerulonephritis and pulmonary haemorrhage. The Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) trial included all comers with a glomerular filtration rate <50mL/min/1.73m(2) and thus aimed to answer the question of whether PLEX is an option for patients with no relevant kidney function impairment or not. PEXIVAS revealed that after a follow-up of almost 3 years, routine administration of PLEX does not provide an additional benefit to reduce the rate of a composite comprising end-stage kidney disease or death. In the absence of histological parameters, it is tempting to speculate whether PLEX is effective or not in those with a potential for renal recovery. A subset of patients presented with alveolar haemorrhage, and there was a trend towards a better outcome of such cases receiving PLEX. This would be in line with observational studies reporting a recovery of alveolar haemorrhage following extracorporeal treatment. In this PRO part of the debate, we highlight the shortcomings of the PEXIVAS trial and stimulate further research paths, which in our eyes are necessary before abandoning PLEX from the therapeutic armamentarium.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Nephrology, Dialysis, Transplantation
ISSN
0931-0509
e-ISSN
—
Volume of the periodical
36
Issue of the periodical within the volume
2
Country of publishing house
GB - UNITED KINGDOM
Number of pages
5
Pages from-to
227-231
UT code for WoS article
000646225400007
EID of the result in the Scopus database
2-s2.0-85100445546